Lurasidone/Cycloserine

WILMINGTON, Del., June 02, 2026 (GLOBE NEWSWIRE) -- NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) (“NRx Pharmaceuticals” or the “Company”), a clinical-stage biopharmaceutical company, today announced that it intends to offer shares of its common stock, par value $0.001 per share (“Common Stock”) in an underwritten public offering (the “Offering”). The Company also expects to grant to the underwriter of the Offering a 30-day option to purchase up to an additional 15% of the shares of Common Stock sold in the Offering on the same terms and conditions. The Offering is subject to market and other conditions, and there can be no assurance as to whether or when the Offering may be completed or as to the actual size or terms of the Offering. BTIG, LLC is acting as the lead bookrunner for the Offering. Lucid Capital Markets, LLC is acting as joint bookrunning manager for the Offering. The Company currently intends to use the net proceeds from the Offering for working capital and general corporate purposes to support its growth. The shares of Common Stock will be offered pursuant to an effective shelf registration statement on Form S-3 (File No. 333-288205), including a base prospectus, filed with the U.S. Securities and Exchange Commission (the “SEC”) and declared effective by the SEC on December 22, 2025. A prospectus supplement describing the terms of the Offering will be filed with the SEC and will be available on the SEC’s website located at http://www.sec.gov. Copies of the prospectus supplement and the accompanying base prospectus, when available, may be obtained from BTIG, LLC, at 65 East 55th Street, New York, New York 10022 or by telephone at (212) 593-7555, or by email at ProspectusDelivery@btig.com. Before investing in this Offering, interested parties should read in their entirety the preliminary prospectus supplement and the accompanying base prospectus and the other documents that the Company has filed with the SEC that are incorporated by reference in such preliminary prospectus supplement and the accompanying base prospectus, which provide more information about the Company and the Offering. This press release shall not constitute an offer to sell or the solicitation of an offer to buy any of the securities described herein, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. About NRx Pharmaceuticals, Inc. NRx Pharmaceuticals, Inc., is a clinical-stage biopharmaceutical company developing therapeutics based on its NMDA platform for the treatment of central nervous system disorders, specifically suicidal depression, chronic pain, and PTSD. The Company is developing NRX-100 (preservative-free intravenous ketamine) and NRX-101, (oral D-cycloserine/lurasidone). NRX-100 has been awarded Fast Track Designation for the treatment of Suicidal ideation in Depression, including Bipolar Depression. NRX-101 has been awarded Breakthrough Therapy Designation for the treatment of suicidal bipolar depression. NRx has filed an Abbreviated New Drug Application (ANDA), and initiated a New Drug Application filing for NRX-100 for the treatment of suicidal ideation in patients with depression, including bipolar depression. Notice Regarding Forward-Looking Statements The information contained herein includes forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and Section 27A of the Securities Act of 1933, as amended. Forward-looking statements generally include statements that are predictive in nature and depend upon or refer to future events or conditions, and include words such as “may,” “will,” “should,” “would,” “expect,” “plan,” “believe,” “intend,” “look forward,” and other similar expressions among others. Forward-looking statements herein include, but are not limited to, statements regarding the anticipated Offering and the expected use of the proceeds therefrom. Completion of the Offering is subject to numerous factors, many of which are beyond the Company’s control, including, without limitation, market conditions, failure to satisfy customary closing conditions and the risk factors and other matters set forth in the prospectus supplement and accompanying base prospectus included in the registration statement and the documents incorporated by reference therein. The Company has reported regulatory milestones as they have been achieved but has not predicted the outcome of any future regulatory determination. You should not place undue reliance on forward-looking statements since they involve known and unknown risks, uncertainties and other factors which are, in some cases, beyond the Company’s control and which could, and likely will, materially affect actual results, levels of activity, performance or achievements. Any forward-looking statement reflects the Company’s current views with respect to future events and is subject to these and other risks, including uncertainties and assumptions relating to the Company’s operations, results of operations, growth strategy, and, among other things, liquidity. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is set forth in the Company’s most recent Annual Report on Form 10-K, subsequent Quarterly Report on Form 10-Q and other filings with the SEC. Investors and security holders are urged to read these documents free of charge on the SEC’s website at http://www.sec.gov. Except as may be required by applicable law, the Company assumes no obligation to publicly update or revise these forward-looking statements for any reason, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, whether as a result of new information, future events or otherwise. For further information: Brian Korb Managing Partner, astr partners (917) 653-5122 brian.korb@astrpartners.com

EMOCARE is a smartphone-based passive monitoring tool that generates a continuous, real-time measure of depression from patient voice, facial expression, motion, and screen behavior, and is the first passive monitoring tool for psychiatric conditions. Pooled analysis of three prospective observational studies demonstrated 90% within-person concordance between EMOCARE scores and clinician-rated MADRS (r = 0.895; p = 0.016). EMOCARE also achieved strong sensitivity to symptom change against PHQ-9 (ρ = 0.834; p < 0.001) on consecutive-visit measurements. The validated technology is being deployed across the Hope Therapeutics interventional psychiatry network as a patient-facing self-monitoring and safety-net tool. SARASOTA, Fla. and PARIS, May 28, 2026 (GLOBE NEWSWIRE) -- NRx Pharmaceuticals , Inc. (Nasdaq: NRXP) today announced that its strategic partner, Emobot Health, presented a late-breaking poster at the 2026 Annual Meeting of the American Society of Clinical Psychopharmacology (ASCP), reporting the first pooled clinical validation of EMOCARE, the investigational passive, multimodal, smartphone-based “Depression Thermometer” that powers the Emobot app now being deployed across the Hope Therapeutics network of interventional psychiatry clinics. The poster, titled “Continuous Multimodal Passive Monitoring of Depressive Symptoms via Smartphone — Clinical Validation of EMOCARE,” was presented at 11:45 AM ET by Tanel Petelot, CEO and Co-founder of Emobot , and co-authored by NRx Chief Executive Officer Jonathan C. Javitt, M.D., M.P.H. The interim pooled analysis combined three prospective observational studies (EMC1, EMC2-FR, EMC2-BD) in adults with Major Depressive Disorder or Bipolar Disorder, comparing EMOCARE scores against clinician-rated MADRS and HAM-D₁₇ and self-reported PHQ-9 and GAD-7. EMOCARE achieved within-person concordance with clinician-rated MADRS of r = 0.895 (p = 0.016) and consecutive-visit sensitivity to symptom change against PHQ-9 of ρ = 0.834 (p < 0.001), with continuous scores generated across the full follow-up window and a threshold of at least seven valid days per 14-day window confirming signal robustness. “An r = 0.895 within-person concordance with MADRS is exceptional for any digital biomarker, and unprecedented for one that asks nothing of the patient. As we build out the Hope Therapeutics network and advance NRX-100 and NRX-101 toward the patients who need them most, EMOCARE gives our clinicians something they have never had before: a continuous, real-time read on whether a treatment is working between visits. That is how we intend to deliver interventional psychiatry at scale,” said Jonathan C. Javitt, M.D., M.P.H., Founder and Chief Executive Officer of NRx Pharmaceuticals and Chief Executive Officer of Hope Therapeutics. Approximately half of patients with treatment-resistant depression relapse within six to twelve months of an effective intervention, and clinicians often learn of those relapses well after they begin. Episodic instruments such as MADRS, HAM-D₁₇, and PHQ-9 remain the gold standard but are typically administered every two to four weeks, leaving long stretches with no visibility between visits. EMOCARE is designed to fill that gap, and its integration across the Hope Therapeutics clinic network gives NRx a continuous read on patient response alongside the interventional therapies, including TMS, IV ketamine, and hyperbaric oxygen, delivered in those clinics. About Emobot Health Emobot ( ) is a MedTech pioneer based at the Paris Brain Institute (ICM) that has developed the world’s first passive, multimodal AI platform for automated depression assessment and relapse detection. Unlike traditional active monitoring that requires patient interaction, Emobot ’s “Depression Thermometer” runs 100% seamlessly in the background, providing clinicians with real-time insights into mood, sleep, and physical activity. Emobot is a trusted partner for leading academic institutions, including UC San Diego, Yale University, and Johns Hopkins. About NRx Pharmaceuticals, Inc. NRx Pharmaceuticals, Inc. ( ), is a clinical-stage biopharmaceutical company developing therapeutics based on its NMDA platform for the treatment of central nervous system disorders, specifically suicidal depression, chronic pain, and PTSD. The Company is developing NRX-100 (preservative-free intravenous ketamine) and NRX-101, (oral D-cycloserine/lurasidone). NRX-100 has been awarded Fast Track Designation for the treatment of Suicidal ideation in Depression, including Bipolar Depression. NRX-101 has been awarded Breakthrough Therapy Designation for the treatment of suicidal bipolar depression. NRx has filed an Abbreviated New Drug Application (ANDA), and initiated a New Drug Application filing for NRX-100 for the treatment of suicidal ideation in patients with depression, including bipolar depression. About HOPE Therapeutics, Inc. HOPE Therapeutics, Inc. ( ), a subsidiary of NRx Pharmaceuticals, is a healthcare delivery company that is building a best-in-class network of interventional psychiatry clinics to offer ketamine and other neuroplastic medications, transcranial magnetic stimulation (TMS), Hyperbaric Oxygen Therapy, and other lifesaving therapies to patients with suicidal depression and related disorders, together with a digital therapeutic-enabled platform designed to augment and preserve the clinical benefit of NMDA-targeted drug therapy. HOPE is the first network in Florida to offer the AMPA One Day (ONE-D) treatment that combines TMS, physician-prescribed D-cycloserine, and lisdexamfetamine to achieve remission from treatment-resistant depression. Notice Regarding Forward-Looking Statements The information contained herein includes forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and Section 27A of the Securities Act of 1933, as amended. Forward-looking statements generally include statements that are predictive in nature and depend upon or refer to future events or conditions, and include words such as "may," "will," "should," "would," "expect," "plan," "believe," "intend," "look forward," and other similar expressions among others. These statements relate to future events or to the Company's future financial performance, and involve known and unknown risks, uncertainties and other factors that may cause the Company's actual results to be materially different from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. The Company has reported regulatory milestones as they have been achieved but has not predicted the outcome of any future regulatory determination. You should not place undue reliance on forward-looking statements since they involve known and unknown risks, uncertainties and other factors which are, in some cases, beyond the Company's control and which could, and likely will, materially affect actual results, levels of activity, performance or achievements. Any forward-looking statement reflects the Company's current views with respect to future events and is subject to these and other risks, including uncertainties and assumptions relating to the Company's operations, results of operations, growth strategy, and, among other things, liquidity. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is set forth in the Company's most recent Annual Report on Form 10-K and other filings with the Securities and Exchange Commission. Investors and security holders are urged to read these documents free of charge on the SEC's website at . Except as may be required by applicable law, the Company assumes no obligation to publicly update or revise these forward-looking statements for any reason, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, whether as a result of new information, future events or otherwise. For further information: Brian Korb Managing Partner, astr partners (917) 653-5122 brian.korb@astrpartners.com